| Literature DB >> 32308537 |
Tony Mutiso Kiio1, Soyeun Park1.
Abstract
The advantages of atomic force microscopy (AFM) in biological research are its high imaging resolution, sensitivity, and ability to operate in physiological conditions. Over the past decades, rigorous studies have been performed to determine the potential applications of AFM techniques in disease diagnosis and prognosis. Many pathological conditions are accompanied by alterations in the morphology, adhesion properties, mechanical compliances, and molecular composition of cells and tissues. The accurate determination of such alterations can be utilized as a diagnostic and prognostic marker. Alteration in cell morphology represents changes in cell structure and membrane proteins induced by pathologic progression of diseases. Mechanical compliances are also modulated by the active rearrangements of cytoskeleton or extracellular matrix triggered by disease pathogenesis. In addition, adhesion is a critical step in the progression of many diseases including infectious and neurodegenerative diseases. Recent advances in AFM techniques have demonstrated their ability to obtain molecular composition as well as topographic information. The quantitative characterization of molecular alteration in biological specimens in terms of disease progression provides a new avenue to understand the underlying mechanisms of disease onset and progression. In this review, we have highlighted the application of diverse AFM techniques in pathological investigations. © The author(s).Entities:
Keywords: adhesion properties; atomic force microscopy; disease diagnosis; mechanical compliance; molecular recognition; morphology
Mesh:
Substances:
Year: 2020 PMID: 32308537 PMCID: PMC7163363 DOI: 10.7150/ijms.41805
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Figure 1Various AFM-based techniques adapted to investigate biological specimens. The schematic drawings of an experimental technique and a corresponding line scan or force curve were illustrated for each experimental technique.
Morphological changes observed by the AFM topography during disease onset and progression
| Disease | Cells | Imaging condition | Changes from healthy to pathological conditions | Reference |
|---|---|---|---|---|
| Hereditary Spherocytosis | Human Erythrocytes | IC | Decrease in L from 6.51 ± 0.27 nm to 5.92 ± 0.27 nm and in W from 6.22 ± 0.15 nm to 5.81 ± 0.12 nm | |
| Increase in height from 586 ± 120 nm to 1,644 ± 34 nm | ||||
| Decrease in Rp-v from 1,272 ± 48 nm to 1,058 ± 155 nm | ||||
| Decrease in Ra from 287 ± 44 to 215 ± 6 | ||||
| Iron deficiency anemia | Human Erythrocytes | CM | Increase in protein particle size from 8 nm to > 140 nm | |
| Increase in r from 1.01 ± 0.06 to 1.52 ± 0.47 | ||||
| Decrease in H from 1,729 ± 39 nm to 1,518 ± 72 nm | ||||
| Increase in h from 41 ± 6 nm to 403 ± 43 nm | ||||
| Decrease in Rp-v from 1,605 ± 29 nm to 1,154 ± 88 nm | ||||
| Increase in Ra from 582 ± 26 nm to 1,227 ± 91 nm | ||||
| Malaria | Cultured Erythrocytes | CM and IC | Increase in spectrin length from 48 ± 7 nm at ring stage to 64 ± 9 nm at early and middle trophozoite stage, 69 ± 10 nm at late trophozoite stage, and 75 ± 11 nm at schizont stage | |
| Human red blood cells | IC | Changes in spectrin length from 61 ± 14 nm at trophozoites stage, to 62 ± 8 nm at gametocytes stage, and 42 ± 12 nm at stage V gametocytes | ||
| Pox virus | Kidney cells | Live cells | Exocytosis of protein structures: 10-100 nm in diameter | |
| Exocytosis of progeny virus: 200-300 nm in diameter | ||||
| Neurodegenerative diseases | Aβ1-42 fibril | HSI | Observed two growth modes of Aβ1-42: One producing straight fibrils and another producing spiral fibrils |
Abbreviations: Aβ 1-42: amyloid β peptide; CM: contact mode; h: valley height; H: peak height; HSI: high-speed imaging; IC: intermittent Contact; L: length; Ra: surface roughness; Rp-v: peak-to-valley distance; r: ratio of length to width; W: width.
Alteration in mechanical compliance of cells and tissues revealed by the AFM studies during disease progression
| Pathological changes in E | Disease | Samples | Changes from healthy to pathological condition | References |
|---|---|---|---|---|
| Increase | Sickle cell disease | Human erythrocytes | 1.10 ± 0.40 kPa to 3.0 ± 1.09 kPa | |
| Cardiac hypertrophy | Mice ventricular tissues | 13.5 ± 0.665 kPa to 34.1 ± 1.37 kPa | ||
| Aging | Sheep aorta | Lamellar region: Young (36 ± 2.22 Kpa) to old (63 ± 2.95 Kpa) | ||
| Aging | Mice articular cartilage | 23 ± 1.9 kPa at 6 months to 41 ± 2.9 kPa at 12 months | ||
| Decrease | Osteoarthritis | Human chondrocytes | 0.0960 ± 0.009 N/m to 0.0347 ± 0.005 N/m | |
| Human articular cartilage | 83 Kpa to 5.6 kPa | |||
| Mice articular cartilage | 38 ± 3.4 kPa at 6 months to 20 ± 3.4 kPa at 12 months | |||
| Rabbit chondrocytes | 1.43 ± 0.45 Mpa to 0.16 ± 0.08 Mpa | |||
| Type 1 diabetes | Mice islets tissue | ∼3 kPa to ∼284 Pa | ||
| Asthma | Human bronchial tissue | Lower stress: 14.6 ± 8.2 kPa to 7.7 ± 4.0 kPa | ||
| Higher stress: 3.5 ± 1.8 kPa to 1.8 ± 1.0 kPa | ||||
| HIV-1 virus | Virus particles | Immature HIV-1 virus: 0.93 GPa | ||
| Mature HIV-1 virus: 0.44 GPa | ||||
| Nerve injury | Mice neurons | Softening of growth cone about 20 to 40 % |
Abbreviation: E: elastic modulus.
Changes in adhesion properties revealed by the AFM studies during disease progression
| Disease | Sample | Functionalization on the probe | Changes from healthy to pathological conditions | References |
|---|---|---|---|---|
| Type 2 diabetes | Human erythrocyte | None | Increase in AF from 200 ± 38 | |
| Osteoarthritis | Human articular chondrocytes | None | Decrease in AF from 7 ± 3 | |
| Sickle cell diseases | Human red blood cells | Integrin | Increase in ICAM-4 AF after epinephrine treatment from 10.08 ± 0.85 % to 21.41 ± 2.27 % | |
| Inflammatory diseases | Human T-leukemia Jurkat cells and HUVECs | Human junctional adhesion molecule-A antibody | Increase in DA of stimulated HUVEC center from 1 × 10-16 ± 0.42 J to 3 × 10-16 ± 0.55 J and junction from 1 × 10-16 ± 0.45 J to 7 × 10-16 ± 0.58 J | |
| Alzheimer's disease | Cys-Aβ42 | Aβ peptides | Increase in Aβ-Aβ affinity from 0.40 ± 0.16 mM without zinc to 7.50 ± 2.06 mM with zinc ions | |
| Periodontal diseases | Human whole saliva and | Cobalt-nickel-chromium for dental alloy AF: 5.9 nN | ||
| Feldspathic ceramic AF: 7.7 nN | ||||
| Composite resin Amelogen® Plus AF: 7.8 nN | ||||
| Denture base polymer for dental prosthesis AF: 11.6 nN |
Abbreviations: AF: adhesive force; DA: de-adhesion force; HUVEC: human umbilical vein endothelial cell; ICAM-4: intercellular adhesion molecule-4.